Does the media prefer LMAT or NPCE?

In the previous week, LeMaitre Vascular had 1 more articles in the media than NeuroPace. MarketBeat recorded 4 mentions for LeMaitre Vascular and 3 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.57 beat LeMaitre Vascular's score of 1.24 indicating that NeuroPace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroPace 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to BFLY or NPCE?

In the previous week, Butterfly Network had 5 more articles in the media than NeuroPace. MarketBeat recorded 8 mentions for Butterfly Network and 3 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.57 beat Butterfly Network's score of 0.29 indicating that NeuroPace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroPace 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings and valuation, NVCR or NPCE?

NeuroPace has lower revenue, but higher earnings than NovoCure. NeuroPace is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 2.74 -$136.23M -$1.53 N/A NeuroPace $99.99M 5.64 -$21.47M -$0.65 N/A

Is NVCR or NPCE more profitable?

NeuroPace has a net margin of -21.67% compared to NovoCure's net margin of -25.66%. NovoCure's return on equity of -50.82% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -25.66% -50.82% -16.48% NeuroPace -21.67% -108.20% -18.50%

Does the media refer more to NVCR or NPCE?

In the previous week, NovoCure had 1 more articles in the media than NeuroPace. MarketBeat recorded 4 mentions for NovoCure and 3 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.57 beat NovoCure's score of 0.97 indicating that NeuroPace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroPace 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor NPCE or EYE?

In the previous week, NeuroPace had 1 more articles in the media than National Vision. MarketBeat recorded 3 mentions for NeuroPace and 2 mentions for National Vision. NeuroPace's average media sentiment score of 1.57 beat National Vision's score of 0.82 indicating that NeuroPace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive National Vision 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NeuroPace (NPCE) Competitors

$16.53 +0.06 (+0.36%)

Closing price 06/29/2026 04:00 PM Eastern

Extended Trading

$16.68 +0.15 (+0.90%)

As of 06/29/2026 07:57 PM Eastern

Compare

NPCE vs. LMAT, BFLY, PLSE, NVCR, and EYE

Should you buy NeuroPace stock or one of its competitors? MarketBeat compares NeuroPace with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeuroPace include LeMaitre Vascular (LMAT), Butterfly Network (BFLY), Pulse Biosciences (PLSE), NovoCure (NVCR), and National Vision (EYE). These companies are all part of the "medical equipment" industry.

How does NeuroPace compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and NeuroPace (NASDAQ:NPCE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

LeMaitre Vascular has a net margin of 24.35% compared to NeuroPace's net margin of -21.67%. LeMaitre Vascular's return on equity of 15.36% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
NeuroPace	-21.67%	-108.20%	-18.50%

LeMaitre Vascular has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.79	$57.73M	$2.71	35.42
NeuroPace	$99.99M	5.64	-$21.47M	-$0.65	N/A

In the previous week, LeMaitre Vascular had 1 more articles in the media than NeuroPace. MarketBeat recorded 4 mentions for LeMaitre Vascular and 3 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.57 beat LeMaitre Vascular's score of 1.24 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroPace	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

LeMaitre Vascular presently has a consensus price target of $112.60, indicating a potential upside of 17.29%. NeuroPace has a consensus price target of $18.83, indicating a potential upside of 13.93%. Given LeMaitre Vascular's higher possible upside, equities research analysts clearly believe LeMaitre Vascular is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by insiders. Comparatively, 20.5% of NeuroPace shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

LeMaitre Vascular has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market.

Summary

LeMaitre Vascular beats NeuroPace on 11 of the 16 factors compared between the two stocks.

How does NeuroPace compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and NeuroPace (NASDAQ:NPCE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Butterfly Network presently has a consensus price target of $5.56, suggesting a potential downside of 37.85%. NeuroPace has a consensus price target of $18.83, suggesting a potential upside of 13.93%. Given NeuroPace's stronger consensus rating and higher probable upside, analysts clearly believe NeuroPace is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

In the previous week, Butterfly Network had 5 more articles in the media than NeuroPace. MarketBeat recorded 8 mentions for Butterfly Network and 3 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.57 beat Butterfly Network's score of 0.29 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroPace	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

37.8% of Butterfly Network shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 22.0% of Butterfly Network shares are held by company insiders. Comparatively, 20.5% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Butterfly Network has a beta of 2.22, meaning that its share price is 122% more volatile than the broader market. Comparatively, NeuroPace has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market.

NeuroPace has a net margin of -21.67% compared to Butterfly Network's net margin of -73.63%. Butterfly Network's return on equity of -34.41% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-73.63%	-34.41%	-23.91%
NeuroPace	-21.67%	-108.20%	-18.50%

NeuroPace has lower revenue, but higher earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$102.92M	22.14	-$77.06M	-$0.30	N/A
NeuroPace	$99.99M	5.64	-$21.47M	-$0.65	N/A

Summary

NeuroPace beats Butterfly Network on 10 of the 17 factors compared between the two stocks.

How does NeuroPace compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Pulse Biosciences has a net margin of 0.00% compared to NeuroPace's net margin of -21.67%. Pulse Biosciences' return on equity of -86.67% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
NeuroPace	-21.67%	-108.20%	-18.50%

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 20.5% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, NeuroPace had 2 more articles in the media than Pulse Biosciences. MarketBeat recorded 3 mentions for NeuroPace and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.89 beat NeuroPace's score of 1.57 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Pulse Biosciences	Very Positive
NeuroPace	Very Positive

Pulse Biosciences presently has a consensus price target of $30.67, indicating a potential upside of 4.88%. NeuroPace has a consensus price target of $18.83, indicating a potential upside of 13.93%. Given NeuroPace's stronger consensus rating and higher probable upside, analysts clearly believe NeuroPace is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

NeuroPace has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	5,782.00	-$72.78M	-$1.10	N/A
NeuroPace	$99.99M	5.64	-$21.47M	-$0.65	N/A

Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, NeuroPace has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market.

Summary

NeuroPace beats Pulse Biosciences on 12 of the 17 factors compared between the two stocks.

How does NeuroPace compare to NovoCure?

NovoCure (NASDAQ:NVCR) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

84.6% of NovoCure shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 5.5% of NovoCure shares are owned by insiders. Comparatively, 20.5% of NeuroPace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

NeuroPace has a net margin of -21.67% compared to NovoCure's net margin of -25.66%. NovoCure's return on equity of -50.82% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
NeuroPace	-21.67%	-108.20%	-18.50%

NovoCure has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market.

In the previous week, NovoCure had 1 more articles in the media than NeuroPace. MarketBeat recorded 4 mentions for NovoCure and 3 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.57 beat NovoCure's score of 0.97 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroPace	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

NeuroPace has lower revenue, but higher earnings than NovoCure. NeuroPace is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.74	-$136.23M	-$1.53	N/A
NeuroPace	$99.99M	5.64	-$21.47M	-$0.65	N/A

NovoCure currently has a consensus target price of $25.67, indicating a potential upside of 65.81%. NeuroPace has a consensus target price of $18.83, indicating a potential upside of 13.93%. Given NovoCure's higher probable upside, analysts clearly believe NovoCure is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

NeuroPace beats NovoCure on 10 of the 17 factors compared between the two stocks.

How does NeuroPace compare to National Vision?

NeuroPace (NASDAQ:NPCE) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

National Vision has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	5.64	-$21.47M	-$0.65	N/A
National Vision	$1.99B	0.76	$29.60M	$0.57	32.95

78.8% of NeuroPace shares are owned by institutional investors. 20.5% of NeuroPace shares are owned by company insiders. Comparatively, 2.4% of National Vision shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

NeuroPace has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market. Comparatively, National Vision has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

National Vision has a net margin of 2.31% compared to NeuroPace's net margin of -21.67%. National Vision's return on equity of 6.41% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
National Vision	2.31%	6.41%	2.81%

NeuroPace currently has a consensus price target of $18.83, suggesting a potential upside of 13.93%. National Vision has a consensus price target of $30.08, suggesting a potential upside of 60.19%. Given National Vision's higher possible upside, analysts clearly believe National Vision is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
National Vision	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, NeuroPace had 1 more articles in the media than National Vision. MarketBeat recorded 3 mentions for NeuroPace and 2 mentions for National Vision. NeuroPace's average media sentiment score of 1.57 beat National Vision's score of 0.82 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
National Vision	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

National Vision beats NeuroPace on 9 of the 17 factors compared between the two stocks.

Get NeuroPace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NPCE vs. The Competition

Export

Metric	NeuroPace	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$561.52M	$7.36B	$6.85B	$12.20B
Dividend Yield	N/A	1.24%	2.66%	6.22%
P/E Ratio	-25.43	51.01	26.04	24.36
Price / Sales	5.64	83.89	550.14	102.43
Price / Cash	N/A	26.99	29.09	36.93
Price / Book	29.00	7.63	10.98	6.49
Net Income	-$21.47M	$159.19M	$3.57B	$336.61M
7 Day Performance	3.83%	2.17%	2.60%	1.25%
1 Month Performance	-0.06%	-3.34%	0.93%	0.24%
1 Year Performance	48.38%	6.03%	36.40%	30.16%

NeuroPace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NPCE NeuroPace	2.0392 of 5 stars	$16.53 +0.4%	$18.83 +13.9%	+54.3%	$561.52M	$99.99M	N/A	170	Positive News
LMAT LeMaitre Vascular	4.6539 of 5 stars	$92.16 +4.0%	$112.60 +22.2%	+16.3%	$2.11B	$249.60M	34.00	490	Positive News
BFLY Butterfly Network	1.3126 of 5 stars	$7.85 +7.9%	$5.56 -29.1%	+360.2%	$2.00B	$97.61M	N/A	460	Gap Up
PLSE Pulse Biosciences	2.4323 of 5 stars	$26.30 +2.3%	$30.67 +16.6%	+93.9%	$1.82B	$751K	N/A	140	Gap Up
NVCR NovoCure	3.1869 of 5 stars	$14.11 +3.6%	$26.86 +90.4%	-14.0%	$1.64B	$674.41M	N/A	1,605

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NPCE) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroPace (NPCE) Competitors

NPCE vs. LMAT, BFLY, PLSE, NVCR, and EYE

How does NeuroPace compare to LeMaitre Vascular?

Summary

How does NeuroPace compare to Butterfly Network?

Summary

How does NeuroPace compare to Pulse Biosciences?

Summary

How does NeuroPace compare to NovoCure?

Summary

How does NeuroPace compare to National Vision?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NPCE vs. The Competition

NeuroPace Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroPace (NPCE) Competitors

NPCE vs. LMAT, BFLY, PLSE, NVCR, and EYE

How does NeuroPace compare to LeMaitre Vascular?

Is LMAT or NPCE more profitable?

Which has higher earnings and valuation, LMAT or NPCE?

Does the media prefer LMAT or NPCE?

Do analysts rate LMAT or NPCE?

Do insiders and institutionals have more ownership in LMAT or NPCE?

Which has more volatility & risk, LMAT or NPCE?

Summary

How does NeuroPace compare to Butterfly Network?

Do analysts recommend BFLY or NPCE?

Does the media refer more to BFLY or NPCE?

Do institutionals & insiders hold more shares of BFLY or NPCE?

Which has more risk and volatility, BFLY or NPCE?

Is BFLY or NPCE more profitable?

Which has stronger valuation and earnings, BFLY or NPCE?

Summary

How does NeuroPace compare to Pulse Biosciences?

Is PLSE or NPCE more profitable?

Do insiders and institutionals believe in PLSE or NPCE?

Does the media refer more to PLSE or NPCE?

Do analysts rate PLSE or NPCE?

Which has better valuation & earnings, PLSE or NPCE?

Which has more risk and volatility, PLSE or NPCE?

Summary

How does NeuroPace compare to NovoCure?

Do insiders & institutionals believe in NVCR or NPCE?

Is NVCR or NPCE more profitable?

Which has more risk & volatility, NVCR or NPCE?

Does the media refer more to NVCR or NPCE?

Which has higher earnings and valuation, NVCR or NPCE?

Do analysts rate NVCR or NPCE?

Summary

How does NeuroPace compare to National Vision?

Which has higher earnings and valuation, NPCE or EYE?

Do institutionals and insiders hold more shares of NPCE or EYE?

Which has more risk and volatility, NPCE or EYE?

Is NPCE or EYE more profitable?

Do analysts rate NPCE or EYE?

Does the media favor NPCE or EYE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NPCE vs. The Competition

NeuroPace Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools